Results Show Strong Responses for Brentuximab Vedotin Plus N

Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).

Related Keywords

Texas , United States , Massachusetts , Florida , Oregon , Rocky Mountain , Tennessee , California , San Diego , American , Hun Ju Lee , Jeremys Abramson , Alexf Herrera , Sarah Cannon Research Institute , American Society Of Hematology Annual Meeting , Willamette Valley Cancer Institute , Research Center , Florida Cancer Specialists Research Institute , Jo Ann Hagler Center , University Of Texas Md Anderson Cancer Center , Mountain Cancer Centers , American Society Of Clinical Oncology , American Society , Hematology Annual Meeting , Clinical Oncology , Tennessee Oncology , Texas Oncology , Florida Cancer Specialists , Research Institute , Rocky Mountain Cancer Centers , Lugano Classification Revised Staging System , Lymphoma Response , Immunomodulatory Therapy Criteria , Cancer Center , Massachusetts General Hospital ,